Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Emory University
AstraZeneca
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Simcha IL-18, Inc.
UNICANCER
Evopoint Biosciences Inc.